Toggle light / dark theme

Size-shifting nanoparticles successfully deliver mRNA medicine to the pancreas

In recent years, mRNA in lipid nanoparticles (mRNA–LNPs) has emerged as a promising strategy for treating numerous conditions, including COVID-19, various cancers and chronic genetic disorders. To date, this technology has not been successfully used for pancreatic diseases, but that could be about to change. In a paper published in Nature, scientists from China report the development of a new lipid nanoparticle drug-delivery system specifically designed for the pancreas.

Lipid nanoparticles are a special class of fat-based carriers that encapsulate and deliver nucleic acids such as messenger RNA into cells. Among the reasons they have not worked for the pancreas until now is that most LNPs naturally accumulate in the liver and spleen. That means the therapeutic molecules they carry can’t accumulate to high enough levels to be beneficial.

However, the research team realized that while the liver and spleen are wrapped in a dense, protective outer layer called a capsule, the pancreas is only covered by a thin layer of connective tissue. They wondered if these organ capsules act as a biological filter. If so, they could perhaps design nanoparticles large enough to be physically blocked by the walls of the spleen and liver, leaving the pancreas as the only place to go. They named this discovery the capsule-filter-mediated pancreatic-targeted (CAMP) mechanism.

Cellular Reprogramming: The Expert Roundup

Cellular reprogramming is one of the technologies most associated with longevity. The field was created in 2006, when Shinya Yamanaka showed that a cocktail of four transcription factors, commonly known as OSKM, can cause de-differentiation and massive rejuvenation of a cell, creating an iPSC (induced pluripotent stem cell). About a decade later, partial reprogramming was demonstrated in vivo, where a more subtle application of the factors led to rejuvenation without compromising the cell’s identity.

Today, this field is maturing quickly, with its first clinical trials just around the corner. Academic teams and companies are working on dozens of directions and applications. We asked four experts, all involved in reprogramming-related biotech companies, to talk about their companies’ approaches and the opportunities and bottlenecks that the field faces and to offer predictions for the near and not-so-near future.

What I find most compelling about cellular reprogramming is that it revealed aging to be, at least in part, an actively maintained biological state rather than irreversible accumulation of damage. The discovery that somatic cells retain a latent capacity to reset their epigenetic and functional identity fundamentally changed how we think about cellular plasticity, identity, and time.

BREAKTHROUGH 100% Lifespan Increase With Senovax & Stem Cells! #shorts

Groundbreaking research reveals senolytics combined with stem cells can double lifespan. This isn’t a small improvement; it’s a revolutionary leap in regenerative medicine, supporting a new paradigm. #Longevity #RegenerativeMedicine #StemCells #Senolytics #HealthTech @immortabio

Rejuvenation And Dramatic Lifespan Extension Is Here!

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links/Affiliates:
Blood testing (where I get the majority of my labs): https://www.ultalabtests.com/partners/michaellustgarten.

Blood testing with LifeExtension.com: https://www.anrdoezrs.net/click-101614996-15750394

At-Home Metabolomics: https://www.iollo.com?ref=michael-lustgarten.
Use Code: CONQUERAGING At Checkout.

Clearly Filtered Water Filter: https://get.aspr.app/SHoPY

Epigenetic, Telomere Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7xyIU-LSYLyQdQ6…M0&irgwc=1

AI to help researchers see the bigger picture in cell biology

A new AI framework identifies which data about a cell are captured by one measurement modality and which are shared across multiple modalities. This gives researchers a more complete picture of the cell state and could help them understand disease mechanisms and plan treatments.

Oral Corticosteroid Use During Pregnancy and Gestational Diabetes Risk

Among pregnant women, oral corticosteroid use was not linked to higher rates of gestational diabetes.

No substantial increase in risk was observed among women exposed to OCSs between 1 and 27 weeks’ gestation, except for a slight increase during weeks 4–6. The findings remained consistent across age groups, indications, doses, and durations.


Question Does oral corticosteroid use during pregnancy increase the risk of gestational diabetes?

Findings In this cohort study of 1 325 940 pregnancies resulting in live births, oral corticosteroid use between 1 and 27 weeks’ gestation was not associated with an increased risk of gestational diabetes compared with unexposed pregnancies.

Meaning These results suggest that oral corticosteroid treatment during pregnancy does not elevate the risk of gestational diabetes and may be considered a reasonable therapeutic option for managing maternal conditions.

Stem cell patch reverses brain damage in fetuses with spina bifida

A patch made of stem cells from donor placentas has been used to treat fetuses in the womb with a severe form of spina bifida as part of a world-first trial. The novel approach seems to have reversed a brain complication associated with the congenital condition at least as effectively as the go-to treatment, but is expected to enable more children to walk over the long term.

The mother of one of the babies, who is now 4 years old, says she expected that her son Toby would require a wheelchair when he was diagnosed with the condition in the womb. “But Toby is healthy [and] has hit all of his milestones – he’s walking, running and jumping – and has no problems with bladder control, which is rare for people with the condition,” she says.

Spina bifida – which affects about 1 in every 2,800 births in the US every year – occurs when a baby’s spine and spinal cord do not fully develop in the womb. In the most severe form of the condition, called myelomeningocele, the spinal cord and its surrounding tissue protrude out of a gap in the vertebrae, which often impairs mobility and bowel and bladder control. The cause of spina bifida is unknown, but folic acid deficiency during pregnancy raises the risk.

One of the standard treatments involves surgery in the womb that tucks the spinal cord and the surrounding tissue back into the vertebrae, before sewing up the skin to form a tight seal. “But many children still end up unable to walk and there’s [usually] no improvement in bowel or bladder control,” says Diana Farmer at the University of California, Davis.

This led Farmer and her colleagues to wonder if the addition of stem cells could help by promoting the growth and repair of spinal tissue. To find out, they recruited six pregnant women carrying fetuses with myelomeningocele.

Read More


A Developmentally Informed Study of Sleep and Circadian Polygenic Scores in Adolescence

Adult sleep GWAS-derived polygenic scores demonstrated comparable associations with corresponding sleep phenotypes in Adolescents, suggesting genetic influences on sleep persist across developmental stages.


Question Do genetic variants that are associated with adult sleep/circadian phenotypes influence sleep phenotypes in adolescents?

Findings In a population-based birth cohort study (N = 3903), genetic influences on all adult sleep phenotypes (sleep duration, insomnia, daytime sleepiness, napping, and chronotype as indexed by polygenic scores derived from adult genome-wide association studies) were associated with their corresponding sleep/circadian phenotypes in adolescents aged 15 years.

Meaning Genetic variants identified in adult genome-wide association studies may also be relevant to a variety of sleep phenotypes in adolescence, suggesting that these variants index sleep phenotypes during a key developmental stage in which sleep disturbances typically emerge.

/* */